JBIO vs ZYME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

JBIO

46.5
AI Score
VS
ZYME Wins

ZYME

50.0
AI Score

Investment Advisor Scores

JBIO

47score
Recommendation
HOLD

ZYME

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric JBIO ZYME Winner
Net Income -96.13M -81.13M ZYME
Operating Income -102.36M -92.55M ZYME
ROE -21.9% -30.2% JBIO
ROA -20.4% -23.4% JBIO
Total Assets 472.11M 346.53M JBIO
Cash 107.25M 41.16M JBIO
Current Ratio 14.93 5.88 JBIO
Free Cash Flow -67.93M -34.53M ZYME

Relative Price Performance (Last 90 Days)

JBIO 1M: -22.9% · 3M: +11.3% ZYME 1M: +5.3% · 3M: +14.3%

Current Technical Phase

JBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 31

RSI (14): 31.1 · Price: $17.89

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.5 · Price: $26.24

Fundamentals Snapshot

Metric JBIO ZYME
Market Cap
Forward P/E -6.7 22.5
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% -0.9%
Gross Margin -2.5%
Operating Margin 0.0% -9.2%
EPS -1.07 -2.02
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.